NCT06383897 - Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Healthy

Interventions

DRUG

HS-10398

SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction

DRUG

HS-10398 Placebo

SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14

Trial Locations (1)

Unknown

The Affiliated Hospital of Qingdao University, Qingdao